CBCE The Center for Biomedical Continuing Education
Online Education Log In   
Back to Online Education

Recent Advances in the Classification and Treatment of Peripheral T-Cell Lymphomas

An Archived Webcast
Julie M. Vose, MD
 Release Date: December 14, 2009
 Expiration Date: December 13, 2010
THIS ACTIVITY IS AVAILABLE IN THE FOLLOWING METHODS:
Description
Faculty
 

Estimated Time to Complete Activity: 60 minutes

Click here to download the presentation slides in PDF format.



Statement of Need
 T-cell lymphomas (TCLs) are a biologically diverse group of diseases. Most patients afflicted with TCLs are diagnosed primarily with a subtype of nodal, peripheral TCL (PTCL) or extranodal, cutaneous TCL. Although PTCLs represent approximately 12%-15% of all non-Hodgkin lymphomas in Western populations, they are largely unexplored, and optimal treatment remains ill-defined due to the rarity and heterogeneity of the disease. Attempts to adapt treatment regimens commonly used for B-cell lymphomas have not shown a clinical benefit in most PTCL subtypes; 5-year survival rates remain at 15%-30%. Future clinical trials are needed that focus specifically on PTCL to advance our understanding of the disease and define optimal treatment modalities. Several new and promising therapeutic options have emerged within the past few years that are currently under investigation. At the conclusion of this activity, participants will know how to distinguish the various subtypes of PTCL, appreciate the barriers to definitive diagnosis, and evaluate current and novel treatment options for this disease.  

Target Audience
 This activity is intended for hematologists, oncologists, nurses, pharmacists, physician assistants, and other healthcare professionals interested in the latest advances in the treatment of patients with PTCL. 

Educational Objectives
 Upon completion of this activity, participants will be able to
  1. Discuss the incidence, classification, and difficulty in reaching a definitive diagnosis of PTCL subtypes.
  2. Evaluate current chemotherapy-based treatment options for patients with PTCL.
  3. Assess the safety and efficacy of novel, therapeutic agents currently under investigation  for the treatment of patients with PTCL.


Method of Participation

This activity requires that your computer be configured to access the Internet. A high-speed Internet connection may be required to view large files. The webcast will be available on www.thecbce.com. The webcast will also be a featured program on the CBCE CME app, which may be downloaded from the Apple® App Store for use on the iPhone™ or iPod Touch®.

Credit Request Form
Posttest


Method of Participation for iPhone™ or iPod Touch®
 This activity can be accessed using an iPhone™ or iPod Touch® and will be a featured program on the CBCE CME app, which may be downloaded from the Apple® App Store.

Accreditation
 Physicians: The CBCE™ (The Center for Biomedical Continuing Education) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The CBCE designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in this activity.

Physician Assistants: AAPA accepts certificates of participation for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hour of Category 1 credit for completing this program.

Nurses: The CBCE™ (The Center for Biomedical Continuing Education) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

The CBCE designates this educational activity for 1.0 contact hour.

Accreditation by the American Nurses Credentialing Center’s Commission on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.

Pharmacists: The CBCE™ (The Center for Biomedical Continuing Education) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
CPE Credit: 1.0 contact hours or 0.100 CEU
Universal Program Number: 0195-0000-09-023-H01-P



Webcast Credit Instructions

Successful completion of this activity includes the following:

Participants will receive their certificate 4-6 weeks after the CBCE receives their posttest and form. 



CBCE CME App Credit Instructions
 Successful completion of this activity includes the following:
  • Complete the online posttest and score 70% or above.
  • Complete the online Evaluation and Request for Credit Form.  
Participants will receive their certificates via e-mail 4-6 weeks after submission of the online Evaluation and Request for Credit Form.

Participants of the live activity are not eligible to receive credit for this activity.

Acknowledgement of Commercial Support
 The CBCE gratefully acknowledges the educational grant provided by Allos Therapeutics, Inc. 

Educational Inquiries
 For further information, please contact the CBCE, 1707 Market Place Blvd., Suite 370, Irving, TX 75063; Phone: (214) 260-9024; Fax: (214) 260-0509; E-mail: info@thecbce.com.

Disclaimer
 The content and views presented in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of the CBCE or Allos Therapeutics, Inc. This material has been prepared based on a review of multiple sources of information but is not comprehensive. Participants are advised to critically appraise the information presented, and they are encouraged to consult the available literature on any product or device mentioned in this program. 

Disclosure of Unlabeled Uses
 This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product or consult the latest edition of the Physicians’ Desk Reference. 

Disclosure of Financial Relationships With Any Commercial Interest
 As a provider accredited by the ACCME, it is the policy of the CBCE to require that everyone who is in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest, and identify and resolve all conflicts of interest prior to the educational activity. The CBCE defines “relevant financial relationships” as any amount occurring within the past 12 months.

Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honorarium, ownership interest (eg, stocks, stock options, or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected. The CBCE considers relationships of the person involved in the educational activity to include financial relationships of a spouse or partner.

Faculty who refuse to disclose relevant financial relationships will be disqualified from being a planning committee member, a teacher, or an author, and cannot have control of or responsibility for the development, management, presentation, or evaluation of the educational activity. For an individual with no relevant financial relationship, participants must be informed that no relevant financial relationship exists.

Disclosure of Potential Conflicts of Interest
 The CBCE assesses conflicts of interest with its faculty, planners, and managers of CBCE activities. Identified conflicts of interest are thoroughly evaluated for fair balance, scientific objectivity relative to studies utilized in this activity, and patient-care recommendations. The CBCE is committed to providing participants with high-quality, unbiased, and state-of-the-art education.

The following faculty reported real or apparent conflicts of interest, and these conflicts have been resolved through a peer-review process:

Julie M. Vose, MD    
Grant/Research Support
Allos Therapeutics, Inc.
Applied Molecular Evolution, Inc.
Astellas Pharma US, Inc.
Bristol-Myers Squibb Company
Celgene Corporation
Genentech, Inc.
Genzyme Corporation
GlaxoSmithKline
Millennium Pharmaceuticals, Inc.
Novartis Pharmaceuticals Corporation
Pharmacyclics
Rigel Pharmaceuticals, Inc. 

Institutional Disclosure
 The CBCE receives educational grants from the pharmaceutical industry and other commercial sources. Companies providing grants to the CBCE include the commercial supporter of this activity as well as the manufacturers of certain drugs and/or devices discussed in this activity.

Staff Disclosure
 The CBCE staff have declared they have no financial relationships that require disclosure.




© 2010 The CBCE™. All rights reserved.